Recon: Drugmakers petition Trump for phased tariffs; Texas judge overturns FDA’s LDT regulation
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- HHS starts layoffs of thousands of workers across its agencies (STAT) (Politico) (Reuters)
- Pharma industry lobbies Trump for phased tariffs, sources say (Reuters)
- Trump’s proposed tariffs may cause shortages of Canadian-made drugs in the U.S., analysis finds (STAT)
- Reduce drug spending by drastically simplifying monopolies on drugs (STAT)
- Rollout of ‘miracle’ HIV prevention drug is threatened by Trump cuts to global AIDS relief program (STAT)
- Eli Lilly Threatens Obesity Drug Copycat Makers After Shortage (Bloomberg)
- Updated: J&J’s third talc bankruptcy bid is stopped by Texas federal judge (Endpoints)
- Democratic-led states sue to block Trump from $11 billion health funding cut (Reuters)
- European Commission approves Pfizer's RSV vaccine for adults at increased risk of disease (Reuters)
- England’s NICE Wants Industry Involvement In HTA Sandbox Projects (Pink Sheet)
- Angelini Pharma still keen on deals after failed Recordati bid (Reuters)
- Ceva Animal Health hits $10 billion valuation, eyes IPO (Reuters)
- Emotional whiplash for PTC Therapeutics (STAT)
- Trump tariffs hinder M&A and IPOs in what was supposed to be a blockbuster quarter (Reuters)
- Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15 (Endpoints)
- RNA editing startup raises $155M to bring liver and lung disease therapy into clinic (Endpoints)
- Prazer Therapeutics raises $20M; Carisma lets go of most staff (Endpoints)
- Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia (Endpoints)
- Sanofi continues its bet on R&D by poaching GSK’s head of development (Endpoints)
- Bayer eyes launch of menopause relief, heart drugs this year (Reuters)
- Angelini Pharma still keen on deals after failed Recordati bid (Reuters)
- Axsome to narrow focus of depression drug trial after limited success in initial run (Reuters)
- FAO Publishes Report on Food Safety Aspects of Precision Fermentation (Food Safety)
- The Strategic Importance of Food Industry Conferences (Food Safety)
- Texas judge strikes down FDA’s plan to regulate lab-developed tests (STAT) (Endpoints)
- Talkspace is using AI to make therapy podcasts for patients (Endpoints)
- Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports (Reuters)
- Bausch + Lomb recalls Envista intraocular lenses over safety risks (MedTech Dive)
- Abbott’s TriClip Reduces Severity Of Tricuspid Regurgitation Two-Year Results Confirm (MedTech Insight)
- Exact Sciences Launches Cologuard Plus (MedTech Insight)
- HHS will not enforce gender and sexual orientation requirements for medical records (STAT)
- Cassidy gave himself a difficult task. RFK Jr. isn’t making it any easier on him (STAT)
- FDA tobacco official is removed from post in latest blow to health agency’s leadership (Reuters)
- Ambitious NIH drive to solve brain mysteries faces uncertain future (STAT)
- Vence Bonham, acting chief of National Human Genome Research Institute, ‘unexpectedly’ put on leave (STAT)
- Nearly 2,000 top researchers call on Trump administration to halt ‘assault’ on science (STAT)
- DC court sides with HHS in Vertex's fertility program fight (Endpoints)
- FTC concerned about privacy protections in 23andMe bankruptcy (Reuters)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
